ConductScience.org, home

Paper23945458

A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.

Cusin C and 6 others. J Clin Psychiatry, 2013. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. Papers, record 23945458. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23945458

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
PubMed
Journal
J Clin Psychiatry
PubMed
Year
2013
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.89
iCite
Revised in PubMed
2026-01-28
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cusin CCristina
2Iovieno NNadia
3Iosifescu DVDan V
4Nierenberg AAAndrew A
5Fava MMaurizio
6Rush AJA John
7Perlis RHRoy H

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antidepressive AgentsMajor topic
BenzothiazolesMajor topic
Major Depressive DisorderMajor topic
Depressive Disorder, Treatment-ResistantMajor topic
Adult
Aged
Diagnostic and Statistical Manual of Mental Disorders
Dopamine Agonists
Dose-Response Relationship, Drug
Double-Blind Method
Drug Monitoring
Drug Synergism
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Pramipexole
Psychiatric Status Rating Scales
Remission Induction
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
K23 MH067060NIMH NIH HHSUnited StatesK23MH067060PubMed and NIH
K23-MH67060NIMH NIH HHSUnited StatesK23MH067060PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00231959Effectiveness of Pramipexole for Treatment-Resistant DepressionDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in24308279Pramipexole augmentation in treatment-resistant major depressive disorder.https://conductscience.org/library/papers/24308279

Source PubMed

Download CSV of comments and corrections

References28

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115820269Dopaminergic mechanism of antidepressant action in depressed patients.J Affect Disord2005https://conductscience.org/library/papers/15820269PubMed
211556901Chronic desipramine treatment selectively potentiates somatostatin-induced dopamine release in the nucleus accumbens.Eur J Neurosci2001https://conductscience.org/library/papers/11556901PubMed
314971628
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
Psychol Med2004https://conductscience.org/library/papers/14971628PubMed
410889548Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments.Mol Psychiatry2000https://conductscience.org/library/papers/10889548PubMed
511458990The effect of repeated treatment with pramipexole on the central dopamine D3 system.J Neural Transm (Vienna)2000https://conductscience.org/library/papers/11458990PubMed
67664822Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.Eur J Pharmacol1995https://conductscience.org/library/papers/7664822PubMed
7444788A new depression scale designed to be sensitive to change.Br J Psychiatry1979https://conductscience.org/library/papers/444788PubMed
816279288The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA.Clin Trials2004https://conductscience.org/library/papers/16279288PubMed
93820220Dopamine autoreceptor agonists: resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analogue of apomorphine.J Med Chem1987https://conductscience.org/library/papers/3820220PubMed
1021154393Second-generation antipsychotics for major depressive disorder and dysthymia.Cochrane Database Syst Rev2010https://conductscience.org/library/papers/21154393PubMed
1120708060Pramipexole for stage 2 treatment-resistant major depression: an open study.Prog Neuropsychopharmacol Biol Psychiatry2010https://conductscience.org/library/papers/20708060PubMed
1212479663Pramipexole in treatment-resistant depression: a 16-week naturalistic study.Bipolar Disord2002https://conductscience.org/library/papers/12479663PubMed
1322770672Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder.J Psychiatr Res2012https://conductscience.org/library/papers/22770672PubMed
1410817524Synergistic effect of pramipexole and sertraline in the forced swimming test.Pol J Pharmacol1999https://conductscience.org/library/papers/10817524PubMed
1510812530Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.Depress Anxiety2000https://conductscience.org/library/papers/10812530PubMed
169347387The mesolimbic dopamine system as a target for rapid antidepressant action.Int Clin Psychopharmacol1997https://conductscience.org/library/papers/9347387PubMed
1715669893A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.J Clin Psychiatry2005https://conductscience.org/library/papers/15669893PubMed
1820175941
Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
Int J Neuropsychopharmacol2010https://conductscience.org/library/papers/20175941PubMed
1917335320A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.J Clin Psychiatry2007https://conductscience.org/library/papers/17335320PubMed
209137910The behavioural effects of pramipexole, a novel dopamine receptor agonist.Eur J Pharmacol1997https://conductscience.org/library/papers/9137910PubMed

See all 28 referencesDownload CSV of references

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
42638752Pramipexole treatment and substance use disorder risk in unipolar and bipolar depression: a Swedish nationwide register study.Front Psychiatry2026https://conductscience.org/library/papers/42638752PubMed
42286321Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.Nat Med2026https://conductscience.org/library/papers/42286321PubMed
41057811Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications.BMC Psychiatry2025https://conductscience.org/library/papers/41057811PubMed
40754997Are There Connections between the Neuroendocrine and Dopamine Systems in Bipolar Disorder?Neuroendocrinology2025https://conductscience.org/library/papers/40754997PubMed
38035737Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden.BMJ Open2023https://conductscience.org/library/papers/38035737PubMed
37982928Pramipexole for the Treatment of Depression: Efficacy and Mechanisms.Curr Top Behav Neurosci2024https://conductscience.org/library/papers/37982928PubMed
37109571Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis.Life (Basel)2023https://conductscience.org/library/papers/37109571PubMed
35795852Hydroalcoholic Leaf Extract of Isatis tinctoria L. via Antioxidative and Anti-Inflammatory Effects Reduces Stress-Induced Behavioral and Cellular Disorders in Mice.Oxid Med Cell Longev2022https://conductscience.org/library/papers/35795852PubMed
34986373Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.J Affect Disord2022https://conductscience.org/library/papers/34986373PubMed
34872405Habitual caffeine consumption moderates the antidepressant effect of dorsomedial intermittent theta-burst transcranial magnetic stimulation.J Psychopharmacol2021https://conductscience.org/library/papers/34872405PubMed
34810175PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression.Evid Based Ment Health2022https://conductscience.org/library/papers/34810175PubMed
34404915Influences of dopaminergic system dysfunction on late-life depression.Mol Psychiatry2022https://conductscience.org/library/papers/34404915PubMed
34285088Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications.Pharmacol Rev2021https://conductscience.org/library/papers/34285088PubMed
33658867Experimental Therapeutics in Treatment-Resistant Major Depressive Disorder.J Exp Pharmacol2021https://conductscience.org/library/papers/33658867PubMed
32440593Structural Plasticity Induced by Ketamine in Human Dopaminergic Neurons as Mechanism Relevant for Treatment-Resistant Depression.Chronic Stress (Thousand Oaks)2019https://conductscience.org/library/papers/32440593PubMed
31496702Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study.Neuropsychiatr Dis Treat2019https://conductscience.org/library/papers/31496702PubMed
31376815Sleep therapeutics and neuropsychiatric illness.Neuropsychopharmacology2020https://conductscience.org/library/papers/31376815PubMed
30041971Dopamine Release in Antidepressant-Naive Major Depressive Disorder: A Multimodal [11C]-(+)-PHNO Positron Emission Tomography and Functional Magnetic Resonance Imaging Study.Biol Psychiatry2018https://conductscience.org/library/papers/30041971PubMed
29173175Imaging the Role of Inflammation in Mood and Anxiety-related Disorders.Curr Neuropharmacol2018https://conductscience.org/library/papers/29173175PubMed
29106542Dopamine System Dysregulation in Major Depressive Disorders.Int J Neuropsychopharmacol2017https://conductscience.org/library/papers/29106542PubMed

See all 32 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
DRD41815PubTator's text mininghttps://conductscience.org/library/genes/1815

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
PRAMIPEXOLECHEMBL301265Derived from the trial1https://conductscience.org/library/drugs/CHEMBL301265

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/23945458

GET https://conductscience.org/api/papers/v1/23945458/references?page=2